Brief: Sana Biotechnology, Iaso Biotherapeutics And Innovent Biologics In Non-Exclusive License Agreement For BCMA CAR Construct
10/01/2022 22:20
Jan 10 (Reuters) - Innovent Biologics Inc 1801.HK :
* SANA BIOTECHNOLOGY, IASO BIOTHERAPEUTICS, AND INNOVENT
BIOLOGICS
ANNOUNCE NON-EXCLUSIVE LICENSE AGREEMENT FOR CLINICALLY
VALIDATED BCMA CAR CONSTRUCT
Source text for Eikon: ID:nGNX3FtWkQ
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17